Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 28, 2017
Reporting Period: Event date April 28, 2017
Business Context: The Company is an emerging growth company focused on biopharmaceuticals. This filing reports the entry into a material definitive agreement to facilitate the sale of common stock.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing focuses exclusively on the terms of a new equity sales agreement.
Material Changes
Entry into Material Definitive Agreement: On April 28, 2017, the Company entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. as the sales agent.
Offering Capacity: The agreement allows the Company to offer and sell shares of common stock with an aggregate offering price of up to $30.0 million.
Commission Structure: The Company will pay Cantor Fitzgerald a commission of 3.0% of the aggregate gross proceeds from each sale.
Termination Terms: Either party may terminate the agreement at any time upon ten days' prior notice.
Guidance, Outlook, and Risks
Management Commentary: The Company is not obligated to sell any shares under the agreement. Sales will be made based on the Company's instructions regarding price, time, or size limits.
Method of Sale: Shares may be sold via "at the market offerings" on the NYSE MKT or other existing trading markets at prevailing market prices.
Risks and Contingencies: The offering is subject to customary closing conditions and applicable securities laws. The filing explicitly states it does not constitute an offer to sell shares in any state where such an offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the effective date of the Form S-3 registration statement (File No. 333-217106) referenced in the filing.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific conditions precedent to sales.
- Monitor future filings for actual share sales executed under this agreement and the resulting dilution.
- Confirm the Company's current cash position and burn rate to assess the necessity of utilizing this $30.0 million facility.